openPR Logo
Press release

Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Clinical Trials & Results | Levolta Pharmaceuticals, Inc., Rigel Pharmaceuticals Inc., Chi-Med (Hutchison China MediTech), Genosco Inc, Asana BioSciences, LLC

06-12-2019 12:09 PM CET | Health & Medicine

Press release from: Pharma Proff

Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Clinical

Spleen tyrosine kinase (Syk) is a protein that belongs to the family of tyrosine kinases with an ability to initiate the inflammatory responses, by connecting immune cell receptors to intracellular signaling pathways. Therefore, Syk is an attractive target for improving the symptoms related to acute and chronic inflammation. In addition, the role of protein is recognized as a promoter in various types of cancers ranging from leukemia to retinoblastoma.

Download the sample report @ https://www.pharmaproff.com/request-sample/1198

Syk protein facilitates the phosphorylation of protein on tyrosines and also involves in the B cell antigen receptor (BCR) signalling pathways. There are several drugs that effectively inhibit the Syk kinase but the off-target effect is a limiting factor. Currently, there are various Syk inhibitors that prevent release of inflammatory cytokines in vitro and IgE-driven mast cell degranulation.

Get the detailed analysis @ https://www.pharmaproff.com/report/spleen-tyrosine-kinase-inhibitor

Levolta Pharmaceuticals Inc. is developing a drug candidate, that acts as Syk inhibitor for the treatment of immunological diseases. Rigel Pharmaceuticals Inc. is developing fostamatinib as a Syk inhibitor for the treatment of chronic immune thrombocytopenia and autoimmune hemolytic anemia. Hutchison China MediTech Limited is also developing HMPL-523 as a Syk inhibitor for the treatment of cancer indications. Some of the companies having pipeline of Syk inhibitor include Genosco Inc., Asana BioSciences LLC, and others.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1198

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Clinical Trials & Results | Levolta Pharmaceuticals, Inc., Rigel Pharmaceuticals Inc., Chi-Med (Hutchison China MediTech), Genosco Inc, Asana BioSciences, LLC here

News-ID: 1772719 • Views: 842

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Syk

Global Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics Market Trends, Strong …
Global spleen tyrosine kinase inhibitor therapeutics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned forecast period. Factors such as increasing number of cancer patients, rise in awareness about the kinase inhibitor are propelling the growth of spleen tyrosine kinase (Syk) inhibitor therapeutics market globally. Spleen Tyrosine Kinase (Syk)
Global Tyrosine Protein Kinase SYK Market Research 2019
In this report, we analyze the Tyrosine Protein Kinase SYK Market from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value,
Spleen Tyrosine Kinase (Syk) Inhibitor Therapeutics-Pipeline Analysis 2018
Spleen tyrosine kinase (Syk) is a protein that belongs to the family of tyrosine kinases with an ability to initiate the inflammatory responses, by connecting immune cell receptors to intracellular signaling pathways. Therefore, Syk is an attractive target for improving the symptoms related to acute and chronic inflammation. In addition, the role of protein is recognized as a promoter in various types of cancers ranging from leukemia to retinoblastoma. Download
Tyrosine Protein Kinase SYK Market Share, Leading Players Forecast, Market statu …
In 2018, the global Tyrosine Protein Kinase SYK market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Tyrosine Protein Kinase SYK. This study researches the market size of Tyrosine Protein Kinase SYK, presents the global
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to B Cell Lymphoma 1.1 Outline 1.1.1 Non-Hodgkin’s Lymphoma 1.1.2 Hodgkin’s Lymphoma 1.2 Classification of the B Cell lymphoma 1.2.1 Diffuse Large B Cell Lymphoma 1.2.2 Follicular Lymphoma 1.2.3 Mantle Cell Lymphoma 1.2.4 Burkitt Lymphoma 1.3 Stages of
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7. …
Market Research Hub report titled ‘Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline' Target constitutes close to 28 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase SYK - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or